Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN120290 relative bioavailability crossover study in healthy volunteers
NL-OMON48189Completed
- Sponsor
- Asceneuron SA
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ASN120290 in progressive supranuclear palsy (PSP) (6 arms), sponsored by Asceneuron SA. Primary endpoint: Relative bioavailability based on AUC0-inf. Started May 2019; status: completed.
02
Drugs
ASN120290
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NL-OMON48189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48189.